NASDAQ:BCLI Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis $0.79 0.00 (0.00%) As of 08/7/2026 03:46 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BCLI alerts:Sign Up Key Stats Today's Range$0.75▼$0.8350-Day Range$0.75▼$1.4452-Week Range$0.46▼$1.69Volume11,420 shsAverage Volume18,464 shsMarket Capitalization$8.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function. The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS). NurOwn has received orphan drug designations in multiple jurisdictions and is being evaluated in a pivotal clinical program. In addition to ALS, BrainStorm is exploring potential applications of its cell therapy platform in other neurodegenerative disorders such as multiple sclerosis and Parkinson’s disease. Founded in 2000 and headquartered in Petach Tikva, Israel, BrainStorm maintains research and development operations as well as a current good manufacturing practice (cGMP) cell‐processing facility. The company also operates an office in New York City, facilitating collaborations with U.S. clinical sites and regulatory agencies. This infrastructure supports late‐stage trials and positions BrainStorm for potential commercial supply should regulatory approval be achieved. BrainStorm collaborates with leading academic institutions and regulatory authorities to advance its clinical pipeline while maintaining robust data transparency. Guided by a management team with expertise in regenerative medicine, neurology and biopharmaceutical development, the company aims to address significant unmet medical needs in the global neurodegenerative disease market.AI Generated. May Contain Errors. Read More Receive BCLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BCLI Stock News HeadlinesBrainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?August 1, 2026 | americanbankingnews.comBrainStorm Cell Therapeutics Inc.: BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive ChairmanJuly 28, 2026 | finanznachrichten.deHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.August 10 at 1:00 AM | Stansberry Research (Ad)BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive ChairmanJuly 28, 2026 | prnewswire.comBrainstorm Cell Therapeutics : BCLIJuly 4, 2026 | 247wallst.comBrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative MedicineJune 2, 2026 | prnewswire.comBrainStorm Cell Therapeutics Inc.: BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of DirectorsMay 28, 2026 | finanznachrichten.deBrainStorm Adds Former FDA Leader to BoardMay 28, 2026 | tipranks.comSee More Headlines BCLI Stock Analysis - Frequently Asked Questions How have BCLI shares performed this year? Brainstorm Cell Therapeutics' stock was trading at $0.5530 on January 1st, 2026. Since then, BCLI stock has increased by 42.4% and is now trading at $0.7876. How were Brainstorm Cell Therapeutics' earnings last quarter? Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.07. Read the conference call transcript. When did Brainstorm Cell Therapeutics' stock split? Shares of Brainstorm Cell Therapeutics reverse split on the morning of Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Brainstorm Cell Therapeutics? Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Brainstorm Cell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Company Calendar Last Earnings5/15/2025Today8/10/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BCLI CIK1137883 Webwww.brainstorm-cell.com Phone(201) 488-0460FaxN/AEmployees40Year Founded2004Profitability EPS (Trailing Twelve Months)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.62 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-519.50% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.36) per share Price / Book-0.58Miscellaneous Outstanding Shares11,119,000Free Float8,742,000Market Cap$8.76 million OptionableOptionable Beta0.23 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:BCLI) was last updated on 8/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBarricks gold output fell from 2 million ounces to 719000Barrick's gold production has plunged from 2 million ounces to just 719,000, leaving the world's second-larges...Golden Portfolio | SponsoredTrump's Next Move Could Shrink Your DollarThere's a plan in Washington being called the 'Mar-a-Lago Accord' - a deliberate strategy to weaken the U.S. d...Priority Gold | SponsoredChina is not hedging. It's escaping.China's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredI’ll Keep This Short… (Huge AI Opportunity)Analyst Ross Givens says the top AI opportunity right now isn't Microsoft, Google, Amazon, Apple, or Nvidia - ...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brainstorm Cell Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Brainstorm Cell Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCLI Stock Alerts